Chemotherapy for three months demonstrates lower side effects, suggesting its use as standard care compared with six months.

The US FDA has approved Vyloy in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction cancer.